XG005 for Pain Control in Subjects Undergoing Bunionectomy
Status:
Recruiting
Trial end date:
2024-08-30
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, efficacy, and PK of low dose (750 mg) and high-dose
(1250 mg) XG005 oral tablets compared with placebo in subjects undergoing bunionectomy.
Subjects will be confined in the clinic from check-in through 72 hours post-surgery to
monitor subject safety.